Floatz logo

Cilengitide

Childhood Ependymoblastoma

National Cancer Institute (NCI)protein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Childhood Ependymoblastoma cohort.

Asset / SponsorPhaseRating
Irinotecan
National Cancer Institute (NCI)
Phase 1/2CCC
AZD1775
National Cancer Institute (NCI)
Phase 1/2CCC
cc-5013
National Cancer Institute (NCI)
Phase 1CC
Veliparib
National Cancer Institute (NCI)
Phase 1CC
o6-benzylguanine
National Cancer Institute (NCI)
Phase 1CC

View all 11 →

Same molecule, other indications

Cilengitide is also rated in:

adult glioblastomaDormant
B
Indicative ·
61 / 100
View asset →
gliosarcomaDormant
B
Indicative ·
61 / 100
View asset →
giant cell glioblastomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →